

November 25, 2024

FILED VIA SEDAR

British Columbia Securities Commission

P.O. Box 10142, Pacific Centre
9th Floor, 701 West Georgia Street
Vancouver, BC V7Y 1L2

Alberta Securities Commission

Suite 600, 250 – 5th Street SW
Calgary, AB T2P 0R4

Ontario Securities Commission

20 Queen Street West, 20th Floor
Toronto, ON M5H 3S8

Manitoba Securities Commission

500 – 400 St. Mary Avenue
Winnipeg, MB R3C 4K5

Dear Sirs/Mesdames:

Re: Onco-Innovations Limited (the "Company")

We refer to the prospectus of the Company dated November 25, 2024 relating to an offering of a minimum of 3,000,000 units at \$0.50 per unit for proceeds of \$1,500,000 and up to a maximum of 5,000,000 units at \$0.50 per unit for proceeds of \$2,500,000.

We consent to being named and to the use, through incorporation by reference in the above-mentioned prospectus, of our report dated July 24, 2024 to the shareholders of Onco-Innovations Inc. on the following financial statements:

- Statements of financial position as at April 30, 2024;
- Statements of loss and comprehensive loss, changes in equity and cash flows for the period from January 10, 2024 (date of incorporation) to April 30, 2024.

We report that we have read the prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



SATURNA GROUP CHARTERED PROFESSIONAL ACCOUNTANTS LLP